Search alternatives:
decrease chemotherapy » versus chemotherapy (Expand Search), received chemotherapy (Expand Search), across chemotherapy (Expand Search)
plus chemotherapy » excl chemotherapy (Expand Search), _ chemotherapy (Expand Search)
decrease plant » increased plant (Expand Search), decreases plaque (Expand Search)
Showing 1 - 20 results of 3,954 for search '(( ((decrease chemotherapy) OR (plus chemotherapy)) resistance ) OR ( decrease plant resistance ))', query time: 0.60s Refine Results
  1. 1
    ALDH2 inhibitors decrease stroma-induced ALDH activity in AML cells and sensitize them to chemotherapy.

    ALDH2 inhibitors decrease stroma-induced ALDH activity in AML cells and sensitize them to chemotherapy. by Bin Yuan (19897)

    Published 2020
    Save to List
    Saved in:
  2. 2
    p38 MAPK inhibitor decreases ALDH2 expression in AML cells in the presence of TGF-β1 or stromal cells.

    p38 MAPK inhibitor decreases ALDH2 expression in AML cells in the presence of TGF-β1 or stromal cells. by Bin Yuan (19897)

    Published 2020
    Save to List
    Saved in:
  3. 3
    Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy

    Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy by Ommoleila Molavi (3604277)

    Published 2021
    “…<p><b>Context:</b> Multiple drug resistance is the major obstacle to conventional chemotherapy. …”
    Save to List
    Saved in:
  4. 4
    Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

    Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone by Krishnan Ramaswamy (8430769)

    Published 2020
    Save to List
    Saved in:
  5. 5
    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. Supplementary Material

    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. Supplementary Material by Neeraj Agarwal (53040)

    Published 2022
    Save to List
    Saved in:
  6. 6
    ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer - supplementary material

    ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer - supplementary material by Thomas J. Herzog (6704024)

    Published 2023
    Save to List
    Saved in:
  7. 7
    Image_3_OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.tif

    Image_3_OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-R... by Wei Peng (432211)

    Published 2022
    “…MCF7-BCSCs were constructed by drug-resistance experiment and sphere-formation assay, then DRBC mice were constructed by planting MCF7-BCSCs. …”
    Save to List
    Saved in:
  8. 8
    Image_1_OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.tif

    Image_1_OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-R... by Wei Peng (432211)

    Published 2022
    “…MCF7-BCSCs were constructed by drug-resistance experiment and sphere-formation assay, then DRBC mice were constructed by planting MCF7-BCSCs. …”
    Save to List
    Saved in:
  9. 9
    Image_2_OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.tif

    Image_2_OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-R... by Wei Peng (432211)

    Published 2022
    “…MCF7-BCSCs were constructed by drug-resistance experiment and sphere-formation assay, then DRBC mice were constructed by planting MCF7-BCSCs. …”
    Save to List
    Saved in:
  10. 10
    INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance - PLSP

    INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance - PLSP by Egbert F Smit (9252899)

    Published 2021
    Save to List
    Saved in:
  11. 11
    Supplementary Table 2 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    Supplementary Table 2 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair by Anna Solta (17387538)

    Published 2023
    Save to List
    Saved in:
  12. 12
    Supplementary Table 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    Supplementary Table 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair by Anna Solta (17387538)

    Published 2023
    Save to List
    Saved in:
  13. 13
    Biochemical findings of various group of rats induced with colorectal cancer and treated with Aspirin plus FOLFOX chemotherapy in various combinations.

    Biochemical findings of various group of rats induced with colorectal cancer and treated with Aspirin plus FOLFOX chemotherapy in various combinations. by Mohammed Faruk (8898077)

    Published 2021
    Save to List
    Saved in:
  14. 14
    Supplementary Video – Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer:TALAPRO-2 phase III study design

    Supplementary Video – Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer:TALAPRO-2 phase III study design by Taylor & Francis (465068)

    Published 2022
    Save to List
    Saved in:
  15. 15
    Inhibition of LDHA leads to decreased ATP, reduced AKT phosphorylation, and enhanced chemotherapy sensitivity to LBP in A549 and NCL-H1975 cells.

    Inhibition of LDHA leads to decreased ATP, reduced AKT phosphorylation, and enhanced chemotherapy sensitivity to LBP in A549 and NCL-H1975 cells. by Siyu Yuan (7425719)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 16
    Supplementary Figures S1-S11 from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer

    Supplementary Figures S1-S11 from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer by Fang Fang (38179)

    Published 2023
    Save to List
    Saved in:
  17. 17
    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf

    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf by Bo Li (112195)

    Published 2021
    Save to List
    Saved in:
  18. 18
    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf

    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf by Bo Li (112195)

    Published 2023
    Save to List
    Saved in:
  19. 19
    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf

    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf by Bo Li (112195)

    Published 2021
    Save to List
    Saved in:
  20. 20
    Infographic – INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

    Infographic – INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance by Taylor & Francis (465068)

    Published 2022
    Save to List
    Saved in:

Search Tools: